GT Biopharma, Inc.
GTBP
$0.61
-$0.15-19.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 138.96% | 38.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 123.53% | -21.69% | |||
| Operating Income | -123.53% | 21.69% | |||
| Income Before Tax | -117.31% | -84.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -117.31% | -84.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -117.31% | -84.66% | |||
| EBIT | -123.53% | 21.69% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -50.96% | -65.52% | |||
| Normalized Basic EPS | -52.86% | 31.66% | |||
| EPS Diluted | -50.96% | -65.52% | |||
| Normalized Diluted EPS | -52.86% | 31.66% | |||
| Average Basic Shares Outstanding | 42.17% | 18.20% | |||
| Average Diluted Shares Outstanding | 42.17% | 18.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||